VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Bergstrom on XMT-1536 in Ovarian Cancer

Donald A. Bergstrom, MD, PhD
Published: Tuesday, Oct 04, 2016



Donald A. Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses recent data on the new immunoconjugate, XMT-1Donald A. Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses recent data on the new immunoconjugate, XMT-1536.536.

Using Fleximer technology, Mersana Therapeutics has designed an antibody-drug conjugate that specifically recognizes the NaPi2b protein on the surface of cells, explains Bergstrom. In ovarian cancer tumor models, after patients were given either 1 dose or 3 repeated doses of XMT-1536, they showed complete tumor regression.

This agent is expected to be very well tolerated in future clinical trials, says Bergstrom. Initial indications will likely be for patients with more advanced and/or treatment-resistant disease in the metastatic setting, though they also hold promise for earlier forms of therapy and in combination with immune checkpoint agents.


Donald A. Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses recent data on the new immunoconjugate, XMT-1Donald A. Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses recent data on the new immunoconjugate, XMT-1536.536.

Using Fleximer technology, Mersana Therapeutics has designed an antibody-drug conjugate that specifically recognizes the NaPi2b protein on the surface of cells, explains Bergstrom. In ovarian cancer tumor models, after patients were given either 1 dose or 3 repeated doses of XMT-1536, they showed complete tumor regression.

This agent is expected to be very well tolerated in future clinical trials, says Bergstrom. Initial indications will likely be for patients with more advanced and/or treatment-resistant disease in the metastatic setting, though they also hold promise for earlier forms of therapy and in combination with immune checkpoint agents.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x